Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases

Autor: Giorgia Bodini, Fabrizio Montecucco, Franco Dallegri, Edoardo G. Giannini, Vincenzo Savarino, Federico Carbone, Aldo Bonaventura, Alessandra Vecchié, Matteo Brunacci, I. Baldissarro, Mattia Crespi, Luca Liberale
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Adult
Male
0301 basic medicine
medicine.medical_specialty
Clinical Biochemistry
Pilot Projects
Biochemistry
Inflammatory bowel disease
Gastroenterology
inflammatory bowel diseases
Young Adult
03 medical and health sciences
Internal medicine
medicine
Humans
Prospective Studies
tissue inhibitor of matrix metalloproteinase-2
Mesalamine
Prospective cohort study
Tissue Inhibitor of Metalloproteinase-2
biology
business.industry
Remission Induction
Antibodies
Monoclonal
matrix metalloproteinases
General Medicine
Middle Aged
medicine.disease
digestive system diseases
Pathophysiology
3. Good health
030104 developmental biology
inflammation
Area Under Curve
Myeloperoxidase
Neutrophil elastase
Monoclonal
Cohort
biology.protein
Biomarker (medicine)
Female
matrix metalloproteinases
tissue inhibitor of matrix metalloproteinase-2
inflammatory bowel diseases
inflammation
monoclonal antibodies
monoclonal antibodies
business
Biomarkers
Immunosuppressive Agents
Popis: Background Growing evidence indicates tissue inhibitors of matrix metalloproteinases (TIMPs) as potential players in inflammatory bowel disease (IBD), but, no prospective data are available in IBD remission/relapse. Material & methods In this prospective pilot study, a cohort of IBD patients (n = 32) was enrolled and treated with monoclonal anti-TNF-α antibodies. Patients were clinically followed up for a median period of 54 weeks. Serum circulating levels of C-reactive protein (CRP), TIMP-1 and -2, matrix metalloproteinase (MMP)-9 and -8, myeloperoxidase (MPO) and neutrophil elastase (NE) were assessed by ELISA at enrolment and at the end of the treatment. Results The percentage (%) TIMP-2 reduction from baseline to end of treatment was independently associated with IBD remission at the end of treatment and follow-up as well. ROC curve analysis further confirmed the good prognostic accuracy of % TIMP-2 reduction over the treatment period. Conversely, no other change in inflammatory molecule concentrations was able to predict short- or long-term IBD remission. Conclusions This study indicates TIMP-2 reduction during IBD treatment with monoclonal anti-TNF-α antibodies as a potential prognostic parameter of short and long term remission. To understand if TIMP-2 is an innocent biomarker or an active pathophysiological factor in IBD remains to be clarified.
Databáze: OpenAIRE
Externí odkaz: